ଆସେନାପାଇନ

ଆସେନାପାଇନ
Clinical data
Trade names	Saphris, Sycrest, Secuado, others
Synonyms	Asenapine maleate, ORG-5222
AHFS/Drugs.com	monograph
MedlinePlus	a610015
data	EU EMA: yes; US DailyMed: Asenapine;
Pregnancy; category	AU: C ; ;
Routes of; administration	Under the tongue
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ;
Pharmacokinetic data
Bioavailability	35% (sublingual), <2% (by mouth)
Protein binding	95%
Metabolism	hepatic (glucurinodation by UGT1A4 and oxidative metabolism by CYP1A2)
Elimination half-life	24 hours
Excretion	Kidney (50%), Faecal (40%; ~5–16% as unchanged drug in faeces)
Identifiers
	IUPAC name (3aRS,12bRS)-rel-5-Chloro-2,3,3a,12b-tetrahydro-; 2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole;
ECHA InfoCard	100.059.828
Chemical and physical data
Formula	C17H16ClNO
Molar mass	୨୮୫.୭୭ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Clc4cc2c(Oc1c(cccc1)[C@@H]3CN(C[C@@H]23)C)cc4;
	InChI InChI=1S/C17H16ClNO/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19/h2-8,14-15H,9-10H2,1H3/t14-,15-/m0/s1 ; Key:VSWBSWWIRNCQIJ-GJZGRUSLSA-N ;
(verify)

ଆସେନାପାଇନ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଏକ ବେପାର ନାମ ସଫ୍ରିସ୍, ହେଉଛି ସିଜୋଫ୍ରେ ନିଆ ଓ ବାଇପୋଲାର ଡିଜଅର୍ଡରର ମାନିଆର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ଏକ ଆଟିପିକାଲ୍ ଆଣ୍ଟିସାଇକୋଟିକ୍ ଔଷଧ ।^[୬] ^[୧] ଡିମେନ୍ସିଆ ସମ୍ବନ୍ଧୀୟ ସାଇକୋସିସ ଥିବା ବୟସ୍କ ବ୍ୟକ୍ତିଙ୍କୁ ଏହି ଔଷଧ ଦେଲେ ମୃତ୍ୟୁ ଆଶଙ୍କା ଅଧିକ ହୋଇପାରେ। ^[୬] ଏହା ଜିଭ ତଳେ ଦେଇ ବ୍ୟବହୃତ ହୁଏ ^[୭]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନିଦ୍ରାଳୁ ଭାବ, ମୁଣ୍ଡ ବୁଲାଇବା, ଓଜନ ବୃଦ୍ଧି, ଗତିବିଧି ସମସ୍ୟା ଏବଂ ପାଟି ମଧ୍ୟରେ କାଲୁଆ ହୋଇପାରେ । ^[୬] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଷ୍ଟ୍ରୋକ, ନିଉରୋଲେପ୍ଟିକ୍ ମାଲିଗନାଣ୍ଟ ସିଣ୍ଡ୍ରୋମ, ଟାର୍ଡିଭ୍ ଡିସକାଇନେସିଆ, ମହୁମେହ, ସ୍ୱଳ୍ପ ଶ୍ୱେତ ରକ୍ତ କଣିକା, ବାତ ଏବଂ ଲଙ୍ଗ କ୍ୟୁଟି ସିଣ୍ଡ୍ରୋମ ହୋଇପାରେ। ^[୬] ଏହା କିପରି କାମ କରେ ତାହା ସ୍ପଷ୍ଟ ନୁହେଁ, କିନ୍ତୁ ସେରୋଟୋନିନ୍ ଏବଂ ଡୋପାମାଇନ୍ ରିସେପ୍ଟରଗୁଡିକୁ ଅବରୋଧ କରିବା ସହିତ ଜଡିତ ବୋଲି ବିଶ୍ୱାସ କରାଯାଏ । ^[୧]

୨୦୦୯ ମସିହାରେ ଆମେରିକାରେ ଏବଂ ୨୦୧୦ରେ ୟୁରୋପରେ ଚିକିତ୍ସା ବ୍ୟବହାର ପାଇଁ ଆସେନାପାଇନ ଅନୁମୋଦିତ ହୋଇଥିଲା। ^[୬]^[୧] ପ୍ରଥମ ଜେନେରିକ୍ ସଂସ୍କରଣ ୨୦୨୦ରେ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୮] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୨୧ରେ ପ୍ରତି ମାସରେ ପ୍ରାୟ £୧୦୦ ପାଉଣ୍ଡ ଏଥିପାଇଁ ଖର୍ଚ୍ଚ ହୁଏ । ^[୯] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣ ଔଷଧର ମୂଲ୍ୟ ପ୍ରାୟ ୨୦୦ ଡଲାର ଅଟେ । ^[୧୦]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ "Sycrest EPAR". European Medicines Agency (EMA). Archived from the original on 15 August 2020. Retrieved 9 September 2020.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ "Sycrest 5mg sublingual tablets - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 23 September 2020. Retrieved 9 September 2020.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ "Product Information Saphris (asenapine maleate)" (PDF). TGA eBusiness Services. Merck Sharp & Dohme (Australia) Pty Limited. 14 January 2013. Archived from the original on 2 April 2019. Retrieved 23 October 2013.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ "Saphris (asenapine maleate) tablet". DailyMed. Organon Pharmaceuticals. March 2013. Archived from the original on 3 December 2013. Retrieved 23 October 2013.
↑ ^୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ ^୫.୪ "Product information Sycrest – EMEA/H/C/001177 –II/0012" (PDF). European Medicines Agency. N.V. Organon. 21 February 2013. Archived (PDF) from the original on 28 July 2017. Retrieved 23 October 2013.
↑ ^୬.୦ ^୬.୧ ^୬.୨ ^୬.୩ ^୬.୪ "DailyMed - SAPHRIS- asenapine maleate tablet". dailymed.nlm.nih.gov. Archived from the original on 13 November 2021. Retrieved 16 January 2022.
↑ "Asenapine". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 16 January 2022. Retrieved 16 January 2022.
↑ Research, Center for Drug Evaluation and (23 February 2021). "2020 First Generic Drug Approvals". FDA (in ଇଂରାଜୀ). Archived from the original on 26 September 2021. Retrieved 16 January 2022.
↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 376. ISBN 978-0857114105.
↑ "Asenapine Prices, Coupons & Savings Tips". GoodRx (in ଆମେରିକୀୟ ଇଂରାଜୀ). Archived from the original on 23 October 2016. Retrieved 16 January 2022.

[EPAR2022-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ "Sycrest EPAR". European Medicines Agency (EMA). Archived from the original on 15 August 2020. Retrieved 9 September 2020.

[EMC-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ "Sycrest 5mg sublingual tablets - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 23 September 2020. Retrieved 9 September 2020.

[TGA-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ "Product Information Saphris (asenapine maleate)" (PDF). TGA eBusiness Services. Merck Sharp & Dohme (Australia) Pty Limited. 14 January 2013. Archived from the original on 2 April 2019. Retrieved 23 October 2013.

[DM-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ "Saphris (asenapine maleate) tablet". DailyMed. Organon Pharmaceuticals. March 2013. Archived from the original on 3 December 2013. Retrieved 23 October 2013.

[EMA-5] ୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ ^୫.୪ "Product information Sycrest – EMEA/H/C/001177 –II/0012" (PDF). European Medicines Agency. N.V. Organon. 21 February 2013. Archived (PDF) from the original on 28 July 2017. Retrieved 23 October 2013.

[PI2022-6] ୬.୦ ^୬.୧ ^୬.୨ ^୬.୩ ^୬.୪ "DailyMed - SAPHRIS- asenapine maleate tablet". dailymed.nlm.nih.gov. Archived from the original on 13 November 2021. Retrieved 16 January 2022.

[Liv2022-7] "Asenapine". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 16 January 2022. Retrieved 16 January 2022.

[Gneeric2022-8] Research, Center for Drug Evaluation and (23 February 2021). "2020 First Generic Drug Approvals". FDA (in ଇଂରାଜୀ). Archived from the original on 26 September 2021. Retrieved 16 January 2022.

[BNF81-9] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 376. ISBN 978-0857114105.

[10] "Asenapine Prices, Coupons & Savings Tips". GoodRx (in ଆମେରିକୀୟ ଇଂରାଜୀ). Archived from the original on 23 October 2016. Retrieved 16 January 2022.

[୬]

[୧]

[୭]

[୨]

[୩]

[୪]

[୫]

[୮]

[୯]

[୧୦]